Genentech CDK Inhibitors Patent EP4146647A1
Summary
The European Patent Office published patent EP4146647A1 for CDK inhibitor compositions and methods filed by Genentech, Inc. The patent covers therapeutic applications in cancer treatment (A61P 35/00) with inventors Hu Zhilong, He Hu, Zhang Fei, Zhong Wenge, and Zhu Xiaotian. The patent is designated across 31 European member states including Germany, France, the United Kingdom, Italy, and Spain.
What changed
The European Patent Office granted patent EP4146647A1 to Genentech, Inc. covering CDK (cyclin-dependent kinase) inhibitor compositions and their use in treating cancer. The patent application was filed under IPC classification C07D 471/04 and carries the therapeutic designation A61P 35/00 indicating oncology applications. The publication date is April 1, 2026.
Pharmaceutical companies developing CDK inhibitors for cancer treatment should conduct freedom-to-operate analyses to assess potential licensing requirements or design-around strategies. Competitors in the oncology space may need to monitor Genentech's patent portfolio for strategic implications on their own drug development programs.
What to do next
- Monitor patent landscape for CDK inhibitor-related IP
- Assess freedom-to-operate for oncology programs
- Review licensing opportunities
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CDK INHIBITORS
Publication EP4146647A1 Kind: A1 Apr 01, 2026
Applicants
Genentech, Inc.
Inventors
HU, Zhilong, HE, Hu, ZHANG, Fei, ZHONG, Wenge, ZHU, Xiaotian
IPC Classifications
C07D 471/04 20060101AFI20211112BHEP A61P 35/00 20060101ALI20211112BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.